MovDisordV3, PascalFrancis, Corpus, bibRecord, 001234

The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease

Identifieur interne : 001234 ( PascalFrancis/Corpus ); précédent : 001233; suivant : 001235

The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease

Auteurs : Kazuo Yamashiro ; Miki Komine-Kobayashi ; Taku Hatano ; Takao Urabe ; Hideki Mochizuki ; Nobutaka Hattori ; Yoshitaka Iwama ; Hiroyuki Daida ; Michi Sakai ; Takeo Nakayama ; Yoshikuni Mizuno

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0305148

Descripteurs français

Pascal (Inist)
- Insuffisance valvulaire, Cardiopathie valvulaire, Maladie de Parkinson, Pathologie du système nerveux, Stimulant dopaminergique.

English descriptors

KwdEn :
- Cardiac valvular disease, Dopamine agonist, Nervous system diseases, Parkinson disease, Valvular regurgitation.

Abstract

To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease`
A11	`01`	`1`		`@1 YAMASHIRO (Kazuo)`
A11	`02`	`1`		`@1 KOMINE-KOBAYASHI (Miki)`
A11	`03`	`1`		`@1 HATANO (Taku)`
A11	`04`	`1`		`@1 URABE (Takao)`
A11	`05`	`1`		`@1 MOCHIZUKI (Hideki)`
A11	`06`	`1`		`@1 HATTORI (Nobutaka)`
A11	`07`	`1`		`@1 IWAMA (Yoshitaka)`
A11	`08`	`1`		`@1 DAIDA (Hiroyuki)`
A11	`09`	`1`		`@1 SAKAI (Michi)`
A11	`10`	`1`		`@1 NAKAYAMA (Takeo)`
A11	`11`	`1`		`@1 MIZUNO (Yoshikuni)`
A14	`01`			`@1 Department of Neurology, Juntendo University School of Medicine @2 Tokyo @3 JPN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Department of Cardiology, Juntendo University School of Medicine @2 Tokyo @3 JPN @Z 7 aut. @Z 8 aut.`
A14	`03`			`@1 Department of Health Informatics, Kyoto University School of Public Health @2 Kyoto @3 JPN @Z 9 aut. @Z 10 aut.`
A14	`04`			`@1 Research Institute for diseases of Old Age, Juntendo University School of Medicine @2 Tokyo @3 JPN @Z 11 aut.`
A20				`@1 935-941`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000200276040020`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 08-0305148`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Insuffisance valvulaire @5 01`
C03	`01`	`X`	`ENG`	`@0 Valvular regurgitation @5 01`
C03	`01`	`X`	`SPA`	`@0 Insuficiencia valvular @5 01`
C03	`02`	`X`	`FRE`	`@0 Cardiopathie valvulaire @5 02`
C03	`02`	`X`	`ENG`	`@0 Cardiac valvular disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Cardiopatía valvular @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 04`
C03	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 04`
C03	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 04`
C03	`05`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 09`
C03	`05`	`X`	`ENG`	`@0 Dopamine agonist @5 09`
C03	`05`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
N21				`@1 189`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0305148 INIST
ET :	The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease
AU :	YAMASHIRO (Kazuo); KOMINE-KOBAYASHI (Miki); HATANO (Taku); URABE (Takao); MOCHIZUKI (Hideki); HATTORI (Nobutaka); IWAMA (Yoshitaka); DAIDA (Hiroyuki); SAKAI (Michi); NAKAYAMA (Takeo); MIZUNO (Yoshikuni)
AF :	Department of Neurology, Juntendo University School of Medicine/Tokyo/Japon (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Department of Cardiology, Juntendo University School of Medicine/Tokyo/Japon (7 aut., 8 aut.); Department of Health Informatics, Kyoto University School of Public Health/Kyoto/Japon (9 aut., 10 aut.); Research Institute for diseases of Old Age, Juntendo University School of Medicine/Tokyo/Japon (11 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 7; Pp. 935-941; Bibl. 25 ref.
LA :	Anglais
EA :	To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.
CC :	002B17; 002B17G
FD :	Insuffisance valvulaire; Cardiopathie valvulaire; Maladie de Parkinson; Pathologie du système nerveux; Stimulant dopaminergique
FG :	Pathologie de l'appareil circulatoire; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Valvular regurgitation; Cardiac valvular disease; Parkinson disease; Nervous system diseases; Dopamine agonist
EG :	Cardiovascular disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Insuficiencia valvular; Cardiopatía valvular; Parkinson enfermedad; Sistema nervioso patología; Estimulante dopaminérgico
LO :	INIST-20953.354000200276040020
ID :	08-0305148

Links to Exploration step

Pascal:08-0305148

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease</title>
<author><name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Komine Kobayashi, Miki" sort="Komine Kobayashi, Miki" uniqKey="Komine Kobayashi M" first="Miki" last="Komine-Kobayashi">Miki Komine-Kobayashi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hatano, Taku" sort="Hatano, Taku" uniqKey="Hatano T" first="Taku" last="Hatano">Taku Hatano</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Urabe, Takao" sort="Urabe, Takao" uniqKey="Urabe T" first="Takao" last="Urabe">Takao Urabe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Iwama, Yoshitaka" sort="Iwama, Yoshitaka" uniqKey="Iwama Y" first="Yoshitaka" last="Iwama">Yoshitaka Iwama</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Daida, Hiroyuki" sort="Daida, Hiroyuki" uniqKey="Daida H" first="Hiroyuki" last="Daida">Hiroyuki Daida</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sakai, Michi" sort="Sakai, Michi" uniqKey="Sakai M" first="Michi" last="Sakai">Michi Sakai</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nakayama, Takeo" sort="Nakayama, Takeo" uniqKey="Nakayama T" first="Takeo" last="Nakayama">Takeo Nakayama</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation><inist:fA14 i1="04"><s1>Research Institute for diseases of Old Age, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0305148</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0305148 INIST</idno>
<idno type="RBID">Pascal:08-0305148</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001234</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease</title>
<author><name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Komine Kobayashi, Miki" sort="Komine Kobayashi, Miki" uniqKey="Komine Kobayashi M" first="Miki" last="Komine-Kobayashi">Miki Komine-Kobayashi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hatano, Taku" sort="Hatano, Taku" uniqKey="Hatano T" first="Taku" last="Hatano">Taku Hatano</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Urabe, Takao" sort="Urabe, Takao" uniqKey="Urabe T" first="Takao" last="Urabe">Takao Urabe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Iwama, Yoshitaka" sort="Iwama, Yoshitaka" uniqKey="Iwama Y" first="Yoshitaka" last="Iwama">Yoshitaka Iwama</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Daida, Hiroyuki" sort="Daida, Hiroyuki" uniqKey="Daida H" first="Hiroyuki" last="Daida">Hiroyuki Daida</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sakai, Michi" sort="Sakai, Michi" uniqKey="Sakai M" first="Michi" last="Sakai">Michi Sakai</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nakayama, Takeo" sort="Nakayama, Takeo" uniqKey="Nakayama T" first="Takeo" last="Nakayama">Takeo Nakayama</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation><inist:fA14 i1="04"><s1>Research Institute for diseases of Old Age, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cardiac valvular disease</term>
<term>Dopamine agonist</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Valvular regurgitation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Insuffisance valvulaire</term>
<term>Cardiopathie valvulaire</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Stimulant dopaminergique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>YAMASHIRO (Kazuo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KOMINE-KOBAYASHI (Miki)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HATANO (Taku)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>URABE (Takao)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MOCHIZUKI (Hideki)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HATTORI (Nobutaka)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>IWAMA (Yoshitaka)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>DAIDA (Hiroyuki)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SAKAI (Michi)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>NAKAYAMA (Takeo)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MIZUNO (Yoshikuni)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Cardiology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Health Informatics, Kyoto University School of Public Health</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Research Institute for diseases of Old Age, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>935-941</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000200276040020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0305148</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Insuffisance valvulaire</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Valvular regurgitation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Insuficiencia valvular</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cardiopathie valvulaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cardiac valvular disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Cardiopatía valvular</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>189</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0305148 INIST</NO>
<ET>The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease</ET>
<AU>YAMASHIRO (Kazuo); KOMINE-KOBAYASHI (Miki); HATANO (Taku); URABE (Takao); MOCHIZUKI (Hideki); HATTORI (Nobutaka); IWAMA (Yoshitaka); DAIDA (Hiroyuki); SAKAI (Michi); NAKAYAMA (Takeo); MIZUNO (Yoshikuni)</AU>
<AF>Department of Neurology, Juntendo University School of Medicine/Tokyo/Japon (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Department of Cardiology, Juntendo University School of Medicine/Tokyo/Japon (7 aut., 8 aut.); Department of Health Informatics, Kyoto University School of Public Health/Kyoto/Japon (9 aut., 10 aut.); Research Institute for diseases of Old Age, Juntendo University School of Medicine/Tokyo/Japon (11 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 7; Pp. 935-941; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.</EA>
<CC>002B17; 002B17G</CC>
<FD>Insuffisance valvulaire; Cardiopathie valvulaire; Maladie de Parkinson; Pathologie du   système nerveux; Stimulant dopaminergique</FD>
<FG>Pathologie de l'appareil circulatoire; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Valvular regurgitation; Cardiac valvular disease; Parkinson disease; Nervous system diseases; Dopamine agonist</ED>
<EG>Cardiovascular disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Insuficiencia valvular; Cardiopatía valvular; Parkinson enfermedad; Sistema nervioso patología; Estimulante dopaminérgico</SD>
<LO>INIST-20953.354000200276040020</LO>
<ID>08-0305148</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001234 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001234 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0305148
   |texte=   The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease

The Frequency of Cardiac Valvular Regurgitation in Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri